Amnavero.
← Research directory

Research profile

Tirzepatide

Tirzepatide acts on the GIP and GLP-1 receptors, which are involved in appetite and glucose regulation.

  • Phase 3 clinical trial
  • Evaluation only

SURMOUNT-1 · 72 weeks

Mean weight change

Highest-dose group
−20.9%
Placebo
−3.1%

2,539 adults with obesity or with overweight and a weight-related complication. The trial excluded diabetes.

Phase 3 randomized, double-blind, placebo-controlled trial.

Amnavero Tirzepatide research vial concept packaging
Amnavero Tirzepatide
Concept packaging

How it works

GIP and GLP-1 are hormones involved in the body’s response to food. Tirzepatide activates both receptors. Researchers study how that affects blood sugar, appetite, and body weight.

Tolerability

SURMOUNT-1 · Share of participants
OutcomeHighest-dose groupPlacebo
Nausea31.0%9.5%
Diarrhea23.0%7.3%
Stopped due to adverse events6.2%2.6%

SURMOUNT-4

What happened after stopping?

After 36 weeks on tirzepatide, participants were randomized to continue it or switch to placebo. Over the next 52 weeks, average weight fell a further 5.5% in the continuation group and rose 14.0% in the placebo group, measured from randomization.

What remains uncertain

Both trials excluded people with diabetes. The withdrawal trial randomized people who completed the initial treatment period. The findings leave open how well the results generalize to other groups.